Celcuity (NASDAQ:CELC) Issues Earnings Results

Celcuity (NASDAQ:CELC) announced its quarterly earnings results on Thursday. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.28), Zacks reports. The firm had revenue of $0.09 million during the quarter, compared to analyst estimates of $4.42 million.

Here are the key takeaways from Celcuity’s conference call:

• REVTORPYK was FDA-approved for HR-positive, HER2-negative advanced breast cancer without detected PIK3CA mutations, and both its doublet and triplet regimens received preferred Category 1 recommendations in the NCCN guidelines.
• In the PIK3CA-mutant VIKTORIA-1 cohort, gedatolisib-based regimens significantly improved median progression-free survival to approximately 11 months versus 5.6 months for alpelisib plus fulvestrant, while treatment discontinuation due to adverse events was lower for gedatolisib. Celcuity plans to submit an sNDA in the third quarter of 2026.
• Celcuity remains confident that commercial shipments will begin in late Q3 2026. The company has completed its commercial infrastructure, deployed 88 oncology sales specialists, begun an expanded-access program, and estimates a U.S. addressable market exceeding $6 billion annually.
• The VIKTORIA-2 first-line breast cancer program has been expanded to include endocrine-sensitive patients, potentially broadening gedatolisib’s use across most newly diagnosed advanced HR-positive, HER2-negative patients. Celcuity also expects to provide additional prostate cancer data in Q4 2026.
• Second-quarter net loss widened to $78.9 million from $45.3 million year over year, while selling, general and administrative expenses rose sharply due to launch preparation. The company ended June with $754 million in cash and investments and expects funding into 2029, helped by a $575 million convertible-note offering.

Celcuity Stock Up 6.2%

NASDAQ CELC traded up $5.40 on Friday, hitting $92.00. 1,333,561 shares of the stock were exchanged, compared to its average volume of 1,114,674. The company has a 50-day moving average price of $93.81 and a 200-day moving average price of $108.56. The company has a market cap of $4.49 billion, a PE ratio of -23.59 and a beta of 0.20. Celcuity has a fifty-two week low of $44.42 and a fifty-two week high of $151.02. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04.

Analyst Ratings Changes

Several analysts recently issued reports on CELC shares. HC Wainwright restated a “buy” rating and issued a $155.00 price objective on shares of Celcuity in a report on Friday. Wells Fargo & Company dropped their price target on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Citigroup reiterated an “outperform” rating on shares of Celcuity in a research report on Wednesday, July 15th. Leerink Partners set a $155.00 price target on shares of Celcuity in a research note on Tuesday, June 2nd. Finally, Stifel Nicolaus decreased their price objective on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a report on Friday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $153.64.

Institutional Trading of Celcuity

A number of institutional investors have recently added to or reduced their stakes in the stock. NEA Management Company LLC increased its position in Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after buying an additional 1,391,300 shares in the last quarter. State Street Corp boosted its position in Celcuity by 126.6% in the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after buying an additional 914,887 shares during the last quarter. UBS Group AG grew its stake in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after acquiring an additional 769,891 shares in the last quarter. Deerfield Management Company L.P. acquired a new stake in shares of Celcuity during the third quarter valued at about $36,236,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Celcuity by 107.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,240,281 shares of the company’s stock worth $123,707,000 after acquiring an additional 642,125 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Trending Headlines about Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $155 price target, implying substantial upside from the recent $92 share price. The endorsement reinforces bullish sentiment following Celcuity’s regulatory and commercial progress. Benzinga analyst rating report
• Positive Sentiment: An analyst report maintained a Buy view, citing REVTORPYK/gedatolisib’s FDA approval and rapid NCCN Category 1 inclusion as factors that reduce clinical and adoption risk. Strong VIKTORIA-1 results, including improved efficacy and tolerability, could support rapid physician uptake and a potential blockbuster franchise. Celcuity also reported approximately $754 million in cash, providing funding visibility through 2029 despite elevated launch spending. Celcuity: REVTORPYK Is Now A Commercial Story
• Neutral Sentiment: Stifel Nicolaus maintained a Buy rating but reduced its price target from $175 to $150, while Needham kept a Buy rating and lowered its target from $157 to $140. Both firms remain bullish, but the cuts indicate more cautious near-term assumptions. Benzinga analyst rating reports
• Negative Sentiment: Celcuity’s second-quarter results highlighted commercialization-related financial pressure. The company reported a $1.44 per-share loss, wider than the $1.16 consensus loss, and revenue of only $0.09 million versus the $4.42 million estimate. The results and increased launch-related SG&A prompted analysts to reduce forecasts, although the company’s cash balance provides a substantial operating runway. Celcuity second-quarter 2026 results

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.